Kornimate/medical-research-clean huggingface dataset:
influence of age on trauma femoral fractures

Conditions: FEMORAL FRACTURES

Summary: this study aimed to determine the influence of ageing on the incidence and site of femoral fractures in trauma patients, by taking the sex, body weight, and trauma mechanisms into account.

this retrospective study reviewed data from adult trauma patients aged ≥ 20 years who were admitted into a level i trauma center, between january 1, 2009 and december 31, 2016. according to the femoral fracture locations, 3859 adult patients with 4011 fracture sites were grouped into five subgroups: proximal type a (n = 1,359), proximal type b (n= 1,487), proximal type c (n = 59), femoral shaft (n = 640), and distal femur (n = 466) groups. a multivariate logistic regression analysis was applied to identify independent effects of the univariate predictive variables on the occurrence of fracture at a specific site. the propensity score accounts for the risk of a fracture at a specific femoral site was calculated and presented visually with age in a two-dimensional plot.

Eligibility criteria:
inclusion criteria: * patients to be aged ≥20 years and hospitalized for the treatment of femoral fracture following injury exclusion criteria: * patients with incomplete data were excluded
zactima faslodex trial in postmenopausal advance breast cancer patients instead of zactima faslodex trial

Conditions: Breast Cancer

Summary: the primary objective is to assess the event-free survival defined as the time from randomisation to progression, death without progression, loss to follow up, whichever occurred first..

end-point efficacy: event-free survival (efs)

Eligibility criteria:
inclusion criteria: * post menopausal women with locally advanced or metastatic breast cancer * patients may have either measurable or non-measurable disease, as defined by recist criteria * one previous hormone therapy or one previous chemotherapy for advanced disease are allowed (patients who have stable but evident disease after chemotherapy are eligible) * estrogen receptor positive er+ and/or progesterone receptor positive pr+ on primary or secondary tumour exclusion criteria: * hormone receptor negative tumours (er and pr negative) * presence of life-threatening metastatic visceral disease * significant cardiovascular event (e.g. myocardial infarction, superior vena cava \[svc\] syndrome, new york heart association \[nyha\] classification of heart disease ³2) within 3 months before entry, or presence of cardiac disease that in the opinion of * history of arrhythmia or qtc with bazett's correction unmeasurable or ≥ 480 msec on screening ecg

Keywords: zd6474 vandetanib zactima fulvestrant faslodex breast cancer advanced, metastatic hormone receptor positive post-menopausal patients post-menopausal women with hormone receptor positive advanced breast cancer
assessment of csf shunt flow with thermal measurements b

Conditions: Hydrocephalus

Summary: this study evaluates the performance of a non-invasive thermal measurement device for assessing csf shunt flow. patients with an existing implanted shunt and symptoms of shunt malfunction will be evaluated with the study device.

patients with an existing implanted ventriculoperitoneal (vp) shunt and who are experiencing shunt malfunction symptoms will be recruited by the clinical investigators at each investigational site in accordance with the inclusion and exclusion criteria. assessment of shunt flow will be performed non-invasively with the study device; physician and clinical staff will be blinded to the device result. standard-of-care assessment of shunt function will be performed and surgical intervention will occur based on the judgement of the treating neurosurgeon without the use of study device data. this trial will evaluate the ability of the study device to identify shunt malfunctions.

Eligibility criteria:
inclusion criteria 1. existing ventriculoperitoneal csf shunt on which the patient is dependent 2. at least one symptom of shunt malfunction as determined by the investigator, such as but not limited to seizure, fever, headache, vision problems, dizziness, disorientation, confusion, vomiting, lethargy, irritability, difficulty waking or staying awake, swelling along shunt tract, enlargement of head, loss of balance, gait disturbance, and loss of sensory or motor function 3. suspicion of shunt obstruction warrants the performance of a test for this condition in the investigator's judgement 4. region of intact skin overlying an unambiguously identifiable chronically indwelling ventricular shunt which crosses the clavicle and is appropriate in size for application of the study device 5. available for follow-up for up to seven days 6. signed informed consent by patient or a parent, legal guardian, health care agent, or surrogate decision maker (according to local statutes, and collectively referred to as "surrogates" in this protocol) 7. verbal assent by minors four years of age and older who are able to understand the study and communicate their decision exclusion criteria 1. presence of multiple shunts, or presence of more than one distal shunt catheter (regardless of function) crossing the clavicle ipsilateral to the shunt with suspected obstruction 2. use of the study device would interfere with standard patient care, or emergency surgery that cannot be delayed 3. presence of an interfering open wound or edema over any portion of the shunt 4. patient-reported history of adverse skin reactions to adhesives 5. investigator judges that the subject is likely to be lost to follow-up due to unavailability or clinical outcome being unobtainable 6. participation in the study will interfere with, or be detrimental to, administration of optimal health-care to the subject 7. prior enrollment in this study (multiple main study enrollments of the same patient are disallowed) 8. participation in any other investigational procedural, pharmaceutical, and/or device study that may influence the collection of valid data under this study
a study evaluating the safety, tolerability, and efficacy of aramchol meglumine in primary sclerosing cholangitis

Conditions: Primary Sclerosing Cholangitis

Summary: the objectives of this study is to evaluate the safety, tolerability, and efficacy of aramchol meglumine in patients with primary sclerosing cholangitis

the objectives of this study are to: * establish the safety and tolerability of once daily (qd) aramchol meglumine in patients with psc * examine whether once daily (qd) aramchol meglumine has any effect on serum alkaline phosphatase * provide a comprehensive readout of clinical efficacy following once daily (qd) aramchol meglumine administration

Eligibility criteria:
inclusion criteria: 1. male or female age 18 years and above (inclusive at first screening visit) 2. established diagnosis of large duct psc based on abnormal cholangiography as assessed by magnetic resonance cholangiopancreatography (mrcp) or endoscopic retrograde cholangiopancreatography (ercp) 3. alkaline phosphatase \> 150 iu/l 4. stable inflammatory bowel disease therapy \> 3months for ibd patients 5. if receiving treatment with ursodeoxycholic acid (udca; ursodiol), therapy is at a dose of \<20 mg/kg/day, has been stable for at least 6 months before screening 6. ability to understand the nature of the study and to sign a written informed consent form (icf) exclusion criteria: 1. other causes of liver disease, including secondary sclerosing cholangitis or viral, metabolic, or alcoholic liver disease, as assessed clinically 2. active crohn's disease (cdai \> 40) or ulcerative colitis (mayo ibd score \> 4) or active non-hemorrhoidal rectal bleeding 3. small bowel resection \> 100 cm 4. cirrhosis (clinically evident or by biopsy) 5. prior hepatic decompensation event 6. recent (\< 6 weeks) acute cholangitis or hospitalization for psc or ibd 7. bleeding diathesis or other contraindication for liver biopsy 8. known gi or hepatobiliary malignancy 9. prior liver transplantation 10. prior exposure to study drug 11. active untreated viral hepatitis or other concomitant liver disease
diabetic patients with end-stage renal disease

Conditions: Diabetes; End-Stage Renal Disease; Cardiovascular Diseases

Summary: in diabetic patients with end-stage renal disease to investigate the prevalence of diabetic complications and quality of life and to compare with non-diabetic patients with esrd and diabetic patients with normal kidney function.


Eligibility criteria:
inclusion criteria: * presence of diabetes and treatment with either dialysis or renal transplantation exclusion criteria: * age \< 18 * pregnancy
effect of bronchial artery protection on cough after thoracoscopic lobectomy

Conditions: Cough

Summary: the postoperative complications of thoracoscopic radical surgery for lung cancer mainly include postoperative bleeding, pulmonary infection, chylothorax, nerve injury, pulmonary embolism, arrhythmia, postoperative cough, bronchopleural fistula and so on. among them, postoperative cough is one of the most common complications after lung surgery, and the incidence of postoperative cough is 25% - 50%. cough after pneumonectomy can last for a long time, which affects the rapid recovery of patients after surgery, and brings serious adverse effects to the physiological, psychological and social functions of patients.

after pneumonectomy cough on patients' daily life will bring different degrees of adverse effects, so through certain methods to intervene, in order to reduce the incidence of postoperative cough, accelerate the rapid recovery of patients after surgery, improve the quality of life of patients, which should also be worthy of attention of surgeons. in recent years, the research on intervention measures and treatment methods to reduce cough after thoracoscopic lobectomy is mainly focused on drug treatment, traditional chinese medicine treatment, surgical operation and anesthesia intervention. however, the research on reducing postoperative cough by improving surgical operation is rare. the purpose of this prospective study was to investigate whether preoperative three-dimensional reconstruction and intraoperative protection of bronchial artery can reduce the severity of cough after thoracoscopic lobectomy, so as to further explore the effective intervention measures of postoperative cough and enrich the concept of accelerated rehabilitation surgery.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years, no matter male or female;no cough symptoms within two weeks before operation; lung adenocarcinoma confirmed by pathology;operation method: thoracoscopic lobectomy + systematic lymph node dissection；preoperative abdominal b-ultrasound, skull ct / mri, bone scan or pet / ct to exclude distant metastasis; ecg, lung function, cardiac ultrasound evaluation can tolerate the operation exclusion criteria: * there were cough caused by respiratory diseases, pharyngitis and rhinitis before operation; pneumonia was indicated by chest x-ray or chest ct in recent month;thoracoscopic surgery was converted to thoracotomy;pulmonary arteriovenous angiography could not be performed in patients with allergy to contrast medium; patients and their families refused to be enrolled and followed up.

Keywords: bronchial artery postoperative cough three-dimensional reconstruction thoracoscopic surgery
remote evaluation of the naída ci m90 (marvel) sound processor

Conditions: Cochlear Hearing Loss; Hearing Loss

Summary: within-subject comparison. remotely evaluating latest advanced bionics marvel sound processor for cochlear implants, from two adult groups.

within-subject comparison, standard of care ce marked advanced bionics device. remote evaluation of new ci naida m sound processor through speech understanding in quiet and noise using standard clinical tests, subjective feedback on sound quality for a set of listening situations reflecting everyday use and a ease of use questionnaire. two adult groups, one ci users and the other bimodal users. all tests completed remotely.

Eligibility criteria:
inclusion criteria: * ci users with a ci, hires90k (advantage) or hires ultra cochlear implant system * unilaterally implanted recipients using only a naída q sound processor * bimodal users: additionally using hearing aid on their contralateral ear * minimum of 18 years of age * minimum of five years' experience with their naída q sound processor * minimum of six months experience with their contralateral hearing aid (if applicable) * ability to give feedback on sound quality * speech intelligibility with the bkb sentence test in noise at a +10 db snr \> 10% as obtained during previous visits in the clinical routine or bkb \>50% in quiet conditions if noise has previously not been tested * fluent in english language exclusion criteria: * difficulties additional to hearing impairment that would interfere with the study procedures * concurrent participation in any other clinical hearing study * not due to have their sound processor upgraded in line with normal clinical procedures

Keywords: cochlear implant advanced bionics marvel processor
clinical study to evaluate the handling and safety of avt06 pfs in subjects with chorioretinal vascular disease

Conditions: Chorioretinal Vascular Disease

Summary: this is a single-arm, open label, multicenter clinical study to evaluate the handling and safety of avt06 pre-filled syringe (pfs) in subjects with chorioretinal vascular disease followed by an optional extension phase of avt06 pre-filled syringe (pfs)


Eligibility criteria:
inclusion criteria : * male or female ≥18 years old * subjects with diagnosis of namd (wet), dme, rvo, dr, or myopic cnv in the study eye * study eye considered by the principal investigator to be indicated for treatment with aflibercept * subjects must sign an institutional review board (irb)/independent ethics committee (iec) approved informed consent form (icf) before any study-specific procedures * willing and able to comply with all study procedures and be likely to complete the study * subjects must be able to follow the contraception requirements exclusion criteria (selected): * any concurrent ocular condition in the study eye which, in the opinion of the principal investigator, could either increase the risk to the subject beyond what is to be expected from standard procedures of ivt injections, or which otherwise may interfere with the injection procedure or with evaluation of safety * current systemic infectious disease or a therapy for active infectious disease any condition that, in the principal investigator's opinion, can interfere with full participation in the study, including administration of the study treatment and attending required visits; can pose a significant risk to the subject, or interfere with interpretation of study data
exercise-induced hypoalgesia differences between upper and lower limbs resistance training interventions

Conditions: Local Hypoalgesia; Distal Hypoalgesia; Resistance Training; Pressure Pain Thresholds

Summary: this randomized controlled trial with healthy subjects aims to compare exercise-induced hypoalgesia among three groups: one utilizing a lower limb resistance training intervention, another using an upper limb resistance training, and a control group. the exercise protocol involves 3 sets of 5 repetitions of resistance exercises (brachial biceps curl and leg extensions). exercise-induced hypoalgesia will be assessed by measuring pressure pain thresholds in the thigh and elbow, comparing exercise interventions with the control group. additionally, a secondary objective is to compare the lower limb and upper limb resistance training groups in terms of their effects on pressure pain thresholds in the thigh and elbow. thus, the study anticipates observing differences in local and distal hypoalgesia based on the trained region.


Eligibility criteria:
inclusion criteria: * asymptomatic subjects aged between 18 and 64 years. exclusion criteria: * cardiovascular, respiratory, metabolic, neurological, or osteomuscular signs or pathologies. * history of epilepsy. * pregnant. * participants who present any type of pain on the day of the measurements or who have frequently suffered pain during the previous 12 weeks.
post-market multi-center retro-prospective study to assess long-term clinical outcomes nmsc patients treated with ebx

Conditions: Non-melanoma Skin Cancer

Summary: the purpose of this retrospective-prospective study is to evaluate lesions after treatment for bcc or scc nmsc in order to gain a better understanding of the durability of the treatment, and risk of late toxicities for this patient population.

this is a retrospective-prospective study design. the study is post-market, on-label observational study for the treatment of nmsc. patients who completed treatment at least five years from the last treatment will be identified and existing data as required by this protocol in the patient's record will be collected in addition to conducting office visits or telehealth visits (video) for long-term follow-up. the study will include: identifying patients, retrospectively, who completed treatment a minimum of five years from the last treatment. the history and demographic data will be collected from up to 300 subjects previously treated with ebx for the treatment of nmsc. patients will have an office visit or telehealth visit in order for the investigators to assess the lesion site, document absence of recurrence, treatment for recurrence (if applicable), and long-term toxicities at the time of the prospective visit.

Eligibility criteria:
inclusion criteria: 1. previously completed treatment for non-melanoma skin cancer using xoft ebx electronic brachytherapy system according to standard of care;16 2. provides informed consent; 3. greater than 40 years of age; 4. pathological diagnosis confirmed to be squamous cell carcinoma, or squamous cell carcinoma-in-situ, or basal cell carcinoma prior to treatment; 5. cancer staging included in this study: stage 0: tis, n0, m0 stage 1: t1a, b, c, n0, m0 stage 2: t2a, n0, m0 exclusion criteria: 1. target area is adjacent to a burn scar; 2. any prior definitive surgical resection of the cancer, prior to radiation treatment; 3. known perineural invasion; 4. actinic keratosis; 5. known spread to regional lymph nodes; 6. known metastatic disease; 7. lesion treated with mohs surgery.

Keywords: nmsc
the effect of time-slot scheduling on flu vaccination rates

Conditions: Seasonal Influenza

Summary: the goal of this project is to see if encouraging an individual to privately choose in advance a narrow time window in which to obtain a flu vaccination shot affects the likelihood that he or she will become vaccinated.

influenza causes 36,000 u.s. deaths per year, but influenza immunization rates average just 28%. behavioral "nudges" may increase the effectiveness of immunization reminder mailers at little or no added cost. past psychology research has demonstrated that prompting people to form an implementation plan of the form, "when situation x arises, i will implement response y," increases attainment of desired goals because the desired behavior is linked to a concrete future moment. we study whether adding a planning prompt to a vaccination reminder mailer increases immunization rates.

Eligibility criteria:
inclusion criteria: * seasonal influenza vaccine indications according to the cdc * employees of partner corporations executing study exclusion criteria: * none

Keywords: seasonal influenza behavioral economics nudge implementations intentions vaccination
early-initiated high flow oxygen therapy vs conventional oxygen therapy among patients with ards in the course of sars-cov2 pneumonia.

Conditions: Corona Virus Infection; ARDS Due to Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2; Oxygen Deficiency

Summary: the aim of the study is to compare two methods of oxygen therapy in patients with acute respiratory distress syndrome in the course of sars-cov2 pneumonia. the initial method of oxygen supply during coronavirus pneumonia is conventional oxygen therapy using a face mask or nasal cannula. however, there have been reports in the literature that early initiation of high-flow oxygen therapy with a nasal cannula is associated with better prognosis. the study we perform is intended to provide reliable evidence for confirmation this hypothesis.


Eligibility criteria:
inclusion criteria: 1. the diagnosis of a current sars-cov2 infection (confirmed rt-pcr test or antigen test \[allowed in poland, with sensitivity ≥90 and specificity ≥97\]); 2. hospitalization in the oxygen sector of the temporary hospital in szczecin; 3. pneumonia during sars-cov2 infection; 4. ards (pao 2 / fio 2 ratio ≤300); 5. oxygen flow 8-12 l / min on mask with reservoir and ≤ 60 mmhg pao2 and / or spo2 \< 92%; 6. tno current indications for treatment in the icu; 7. permisson of the patient. exclusion criteria: 1. probable lack of cooperation with patient; 2. severe disease disease, eg generalized neoplastic disease; 3. concomitant pulmonary diseases (eg, fibrosis lungs); 4. respiratory acidosis - ph \ 50 mmhg; 5. disturbances of consciousness - gcs \< 12;

Keywords: sars-cov2, covid-19, hfnc, cot, oxygen therapy.
pre-rehabilitation for female patients undergoing pelvic radiotherapy

Conditions: Dyspareunia; Pelvic Pain; Sexual Dysfunction; Radiation Toxicity

Summary: the purpose of this study is to examine the feasibility of adding pre-rehabilitation pelvic health physical therapy to standard of care radiation therapy treatment plan for female patients who have been diagnosed with cervical, vaginal, vulvar, uterine, or anal cancer and are a candidate for curative pelvic radiation with external beam. participants will receive education on using a vaginal dilator for use during treatment and complete questionnaires looking at pain and sexual function.

because of the increasing survivorship rate, there is a need for research addressing the post-treatment side effects of pelvic pain and dyspareunia, due to the significant impact these side effects have on patients' quality of life. current best practice from trained pelvic health physical therapists for addressing dyspareunia and pelvic pain due to vaginal stenosis after radiation therapy, is vaginal dilation. vaginal dilators are cone shaped durable medical equipment that are inserted into the vagina with lubricant, to assist in patency of the vaginal canal and stretching of the pelvic floor muscles. the primary objective of this pilot clinical trial is to assess the feasibility of implementing a collaborative, coordinated, and multidisciplinary initiative between radiation oncology and pelvic health physical therapy to answer the following questions: 1) what are the barriers and facilitators to the implementation of a pre-rehabilitation service for gynecological and female anal cancer patients undergoing pelvic radiation and 2) what is the potential clinical value of adding pre-rehabilitative pelvic health services, with an emphasis on vaginal dilator education and use, to the gynecological and female anal cancer radiation setting, in collaboration with radiation oncology staff, as a means of reducing pelvic pain and dyspareunia?

Eligibility criteria:
inclusion criteria: 1. female 2. ≥ 18 years old at the time of informed consent 3. ability to provide written informed consent and hipaa authorization 4. primary diagnosis of cervical, vaginal, vulvar, uterine, or anal cancer 5. candidate for curative pelvic radiation with external beam, with or without brachytherapy, per radiation oncologist's discretion notes: * can have prior and/or current modalities of treatment to address diagnosis including surgery and chemotherapy * can receive radiation at any facility provided patient is able to perform physical therapy visits at iuh north/schwarz cancer center exclusion criteria: 1. major medical illnesses or psychiatric impairments, which in the investigator's opinion will prevent administration or completion of the protocol therapy and/or interfere with follow-up. 2. not a candidate for curative radiation therapy per radiation oncologist's discretion 3. prior radiation therapy to the pelvis 4. women who are pregnant or nursing

Keywords: vaginal dilator pelvic health physical therapy